Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification-Reference-Cited by-同舟云学术

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Published:2021-02-08 Issue:8 Volume:17 Page:1365-1382
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Izzo Nicholas J.¹,Yuede Carla M.²,LaBarbera Kelsie M.¹,Limegrover Colleen S.¹,Rehak Courtney¹,Yurko Raymond¹,Waybright Lora¹,Look Gary¹,Rishton Gilbert¹,Safferstein Hank¹,Hamby Mary E.¹,Williams Claire¹,Sadlek Kelsey¹,Edwards Hannah M.²,Davis Charles S.³,Grundman Michael⁴⁵,Schneider Lon S.⁶,DeKosky Steven T.⁷,Chelsky Daniel⁸,Pike Ian⁹,Henstridge Christopher¹⁰,Blennow Kaj¹¹¹²,Zetterberg Henrik¹¹¹²¹³,LeVine Harry¹⁴,Spires‐Jones Tara L.¹⁵,Cirrito John R.²,Catalano Susan M.¹

Affiliation:

1. Cognition Therapeutics Inc. Pittsburgh Pennsylvania USA

2. Washington University St. Louis Missouri USA

3. CSD Biostatistics Inc. Oro Valley Arizona USA

4. Global R&D Partners San Diego California USA

5. University of California San Diego San Diego California USA

6. Keck School of Medicine of USC Los Angeles California USA

7. McKnight Brain Institute University of Florida Gainesville Florida USA

8. Caprion Biosciences Montreal Quebec Canada

9. Proteome Sciences London UK

10. University of Dundee School of Medicine Dundee UK

11. University of Gothenburg Mölndal Sweden

12. Sahlgrenska University Hospital Mölndal Sweden

13. UCL Institute of Neurology London UK

14. Sanders‐Brown Center on Aging University of Kentucky Lexington Kentucky USA

15. The University of Edinburgh Edinburgh UK

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12302

Reference94 articles.

1. Alzheimer's disease drug development pipeline: 2019

2. The amyloid hypothesis of Alzheimer's disease at 25 years

3. The Discovery of Alzheimer causing Mutations in the APP Gene and the Formulation of the “Amyloid Cascade Hypothesis;Hardy J;FEBS J,2017

4. Amyloid β-protein and beyond: the path forward in Alzheimer’s disease

5. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease;Neurobiology of Disease;2024-09

2. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease;Alzheimer's & Dementia;2024-08-21

3. Multi-target drugs for Alzheimer's disease;Trends in Pharmacological Sciences;2024-07

4. BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives;Journal of Alzheimer's Disease;2024-06-22

5. P2Y1 receptor in Alzheimer’s disease;Neural Regeneration Research;2024-05-13